The present invention relates to a fusion protein having formula (I)
X.sub.1−Y−X.sub.2  (I),
wherein X.sub.1 and X.sub.2 comprise each four to six allergen fragments or variants thereof fused to each other, wherein said allergen fragments are derived from at least two allergens of the genus Dermatophagoides, and wherein Y is a carrier protein.

An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

An antigenic peptide comprises the structure X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-P-X.sub.9-X.sub.10-X.sub.11-X.sub.12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X.sub.1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X.sub.2 is E or S, wherein E and S are as defined above; X.sub.3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X.sub.4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X.sub.5 is P or A as defined above; X.sub.6 is V, A or S, wherein V is valine and A and S are as defined above; X.sub.7 is D or S as defined above; X.sub.9 is D or A as defined above; X.sub.10 is N, S or A, wherein N, S and A are as defined above; X.sub.11 is E, A or S, wherein E, A and S are as defined above; X.sub.12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above. The structure comprises at least one mutation compared to the wild type L-E-D-M-P-V-D-P-D-N-E-A sequence. The peptide does not comprise the dipeptide Y-E immediately following X12, wherein Y is tyrosine and E is as defined above. The peptides are conjugated to a suitable carrier and useful in treating synucleinopathies.

The disclosure provides methods and compositions for increasing immunity against coronaviruses, in particular highly pathogenic coronaviruses. Compositions are provided comprising peptides comprising at least a part of the S2 ectodomain of the S (spike) protein from at least one human coronaviruses (HCoV) selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1, as well as compositions comprising nucleic acid molecules encoding at least a part of the S2 ectodomain of the S (spike) protein from at least one human coronaviruses (HCoV) selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1. Compositions described herein are particularly useful as vaccines, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.

The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.

The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewis.sup.a (sLe.sup.a). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLe.sup.a. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

The present invention relates to vaccine compositions comprising lipid antigens, antibodies targeting lipid antigens, pharmaceutical compositions comprising such and their use in diagnosing, monitoring, treating, and preventing infectious disease, such as Lyme disease. In one aspect, administered is a therapeutically effective amount of a vaccine composition comprising a lipid antigen, an antibody or fragment thereof binding a lipid antigen, and/or a pharmaceutical composition comprising an antibody or fragment thereof binding a lipid antigen. Other aspects are described.

The present disclosure relates generally to methods for determining whether a patient will show an enhanced immunogenic response to vaccines when using β-glucan as a vaccine adjuvant. Kits for use in practicing the methods are also provided

Provided herein are antibodies, such as immunoglobulins Y (IgY) antibodies that inhibit beta-lactamase activity, e.g., TEM-1 beta-lactamase, as well as related compositions and methods of use thereof to treat infections by lactam-based antibiotic bacteria that produce beta-lactamase that can degrade antibiotics.